About BIOCHINA2024(EBC)

Originated from 2016, BIOCHINA2024(EBC) is a convention with a scale of more than 20,000 participants. Associating with the scientific research, biotech and biopharma companies, government regulation agencies, and clinical institutions, the convention connected each sectors together for advancing the bio ecosystem in China. “Exhibition-Conference-Event”, are the three major components of BIOCHINA2024(EBC) - The exhibition covers raw materials, reagents, consumables, instruments and equipment, and technical services. The conference covers antibody drugs, cell and gene therapy, nucleic acid drugs, IVD, vaccine, and other innovative development categories. BIOCHINA2024(EBC) initiated with entrepreneurs, investors, scientists, and clinical experts to spreading their thoughts and inspirations of new technologies and projects.

Previous Session of Expert Committee

Cai Daqing

Founding Managing Partner

Sherpa Healthcare Partners

Fang Jianmin

Co-Founder, CEO

RemeGen Co., Ltd.

Ge Junyou

CEO

Kelun Biotech

Gong Zhaolong

Chairman & CEO

3D Medicines

Li Bin

Chairman & CEO

neurophth

Li Jin

Professor

Shanghai East Hospital

Li Ning

GM

Junshi Biosciences

Li Yiping

CEO

JW Therapeutics

Liu Datao

CEO

Mabwell Biosciences

Shen Lin

Chief Physician&Professor

Peking University Cancer Hospital

Tao Weikang

VP of Qilu Pharma, GM of Global Innovative Drug R&D Center

Qilu Pharmaceutical

Ying Bo

Founder & CEO

ABOGEN

Zhang Jinhua

Chairman & CEO

IASO Biotherapeutics

Zhang Lianshan

Director, Deputy GM

Hengrui Pharmaceutical

Zhu Zhongyuan

Founder & CEO

Yingen Biotechnology

Previous Session of BIOCHINA2023(EBC) Exhibition

Previous Session of Conference

Previous Session of Event

Previous Session of Supporting Units

Previous Session of Media Partners